Table 2 Comparison of age of patients at breast cancer diagnosis, molecular subtype, expression of estrogen and progesterone receptor, and HER2 status among the five Brazilian geographic regions
From: Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil
Variable | Brazilian geographic regions | p-value | |||||
|---|---|---|---|---|---|---|---|
SE | S | NE | CW | N | |||
Age | (mean ± SD) | 56.1 ± 13.5 | 55.8 ± 13.9 | 55.3 ± 13.7 | 54.3 ± 12.8 | 53.9 ± 13.1 | <0.0001a |
Molecular subtype | Luminal A | 707 (28.8%) | 324 (30.8%) | 226 (24.1%) | 143 (25.9%) | 171 (25.3%) | <0.0001b |
Luminal B | 971 (39.5%) | 388 (36.9%) | 348 (37.1%) | 190 (34.6%) | 208 (30.8%) | ||
Triple-positive | 238 (9.7%) | 114 (10.8%) | 100 (10.7%) | 71 (12.9%) | 68 (10.1%) | ||
HER2 | 195 (7.9%) | 71 (6.7%) | 99 (10.5%) | 49 (8.9%) | 91 (13.5%) | ||
Triple-negative | 345 (14.0%) | 154 (14.6%) | 163 (17.4%) | 96 (17.4%) | 137 (20.3%) | ||
Non-availablec | 4 | 5 | 3 | 2 | 3 | ||
ER/PR | Positive | 2039 (82.8%) | 871 (82.5%) | 753 (80.0%) | 418 (75.9%) | 529 (78.0%) | 0.0003b |
Negative | 422 (17.1%) | 185 (17.5%) | 188 (20.0%) | 133 (24.1%) | 149 (22.0%) | ||
HER2 | Positive | 433 (17.6%) | 188 (17.8%) | 201 (21.3%) | 119 (21.6%) | 163 (24.0%) | 0.017b |
Negative | 1972 (80.1%) | 846 (80.1%) | 725 (77.0%) | 422 (76.6%) | 506 (74.6%) | ||
Score2+ | 56 (2.3%) | 22 (2.1%) | 15 (1.6%) | 11 (2.0%) | 9 (1.3%) | ||
Total | 2461 | 1056 | 941 | 551 | 678 | ||